Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma - Top-Institutions - MDSpire

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • By

  • February 9, 2026

  • 3 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Cell Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cell Therapy
    • Neuro-oncology

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Cell Therapy

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy
    • Neuro-oncology

Original Source(s)

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

  • by

  • February 9, 2026

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy